Newer chemotherapeutic agents bring concerns in patient care
The use of newer and more targeted chemotherapeutic agents can lead to atypical side effects affecting the skin, hair and nails of oncology patients, and these side effects can be different from those typically seen with longer-standing agents, says Beth N. McLellan, M.D., Ronald O. Perelman Department of Dermatology, New York University, New York.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.